Margaret R. Hammerschlag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Margaret R. Hammerschlag has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Stephan A. Kohlhoff
SUNY Downstate Medical Center, Division of Infectious Diseases, Department of Pediatrics , 450 Clarkson Ave., Brooklyn, NY 11203-2098 , USA
5 shared publications Stephan Kohlhoff
Department of Pediatrics, Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA
5 shared publicationsRoopali Sharma
Department of Pharmacy Practice, Touro College of Pharmacy, New York, NY, USA
4 shared publicationsStephan A. Kohlhoff
Department of Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY, USA
4 shared publicationsPatricia M. Roblin
Division of Pediatric Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center
3 shared publications- Patricia Roblin
Emergency Preparedness Division, SUNY Downstate Health Sciences University, Brooklyn, NY, United States
3 shared publications
Latest Publications
- 25 January 2023
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (3) , e95-e97
Diagnostic Challenges of Urinary Schistosomiasis Among Adolescent Immigrants in New York City: A Report of Three Cases
Urinary schistosomiasis is endemic in the tropical world. It is uncommon in geographical areas with advanced public health resources. Modern immigration from endemic communities to the United States supports the need to improve our diagnostic awareness. We describe 3 Brooklyn adolescent immigrants from Africa with urinary schistosomiasis, all of whom had an initial misdiagnosis that led to delay in therapeutic intervention.
- 25 January 2023
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (3) , e95-e97
Diagnostic Challenges of Urinary Schistosomiasis Among Adolescent Immigrants in New York City: A Report of Three Cases
Urinary schistosomiasis is endemic in the tropical world. It is uncommon in geographical areas with advanced public health resources. Modern immigration from endemic communities to the United States supports the need to improve our diagnostic awareness. We describe 3 Brooklyn adolescent immigrants from Africa with urinary schistosomiasis, all of whom had an initial misdiagnosis that led to delay in therapeutic intervention.
- 17 August 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (9) , AAC0058521
In Vitro Activity of Nafithromycin (WCK 4873) against Chlamydia pneumoniae
Nafithromycin (13 WCK 4873) is a novel lactone ketolide under clinical development as an orally administrated antibiotic for treatment of community acquired pneumonia (CAP) caused by Streptococcus pneumoniae, Hemophilus influenzae, Moraxella catarrhalis, and methicillin susceptible Staphylococcus aureus.…
- 17 August 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (9) , AAC0058521
In Vitro Activity of Nafithromycin (WCK 4873) against Chlamydia pneumoniae
Nafithromycin (13 WCK 4873) is a novel lactone ketolide under clinical development as an orally administrated antibiotic for treatment of community acquired pneumonia (CAP) caused by Streptococcus pneumoniae, Hemophilus influenzae, Moraxella catarrhalis, and methicillin susceptible Staphylococcus aureus.…
- 15 December 2020
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 48 (9) , e122-e123
Universal Prenatal Screening and Testing and Chlamydia trachomatis Conjunctivitis in Infants
We retrospectively reviewed all infant Chlamydia trachomatis eye cultures submitted to the Chlamydia Research Laboratory from 1986 to 2002. The positivity rate was 15.6% during the period before the implementation of universal prenatal screening (1986–1993) compared with 1.8% during the screening period (1994–2002).
- 15 December 2020
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 48 (9) , e122-e123
Universal Prenatal Screening and Testing and Chlamydia trachomatis Conjunctivitis in Infants
We retrospectively reviewed all infant Chlamydia trachomatis eye cultures submitted to the Chlamydia Research Laboratory from 1986 to 2002. The positivity rate was 15.6% during the period before the implementation of universal prenatal screening (1986–1993) compared with 1.8% during the screening period (1994–2002).
- 18 October 2020
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 19 (4) , 487-493
Azithromycin in the treatment of rectogenitalChlamydia trachomatisinfections: end of an era?
Azithromycin was recommended as the first-line therapeutic regimen for treatment of genital infections in men and women by the Centers for Disease Control in 1998. A series of studies of azithromycin for treatment of rectal chlamydial infection in men who have sex with men (MSM) found that azithromycin was significantly less effective than doxycycline. Literature on treatment of rectal C. trachomatis from 2000 through May 2020 was searched using PubMed. Retrospective and observational studies were identified documenting the frequency and treatment of rectal chlamydial infection in MSM, heterosexual men and women that reported lower efficacy of single-dose azithromycin compared to doxycycline. Literature on possible reasons for the lower efficacy were also reviewed including studies of antibiotic resistance, impact of organism load, and persistent infection in rectal specimens and pharmacokinetics and pharmacodynamics of azithromycin in rectal tissue. The available data suggests that single-dose azithromycin is not as effective as azithromycin for the treatment of rectal infection in MSM and women. Most of these data have been retrospective or from observational studies. Final recommendations will depend on the outcome of prospective, randomized, treatment studies. We may also need to examine other dosage regimens for azithromycin.
- 18 October 2020
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 19 (4) , 487-493
Azithromycin in the treatment of rectogenitalChlamydia trachomatisinfections: end of an era?
Azithromycin was recommended as the first-line therapeutic regimen for treatment of genital infections in men and women by the Centers for Disease Control in 1998. A series of studies of azithromycin for treatment of rectal chlamydial infection in men who have sex with men (MSM) found that azithromycin was significantly less effective than doxycycline. Literature on treatment of rectal C. trachomatis from 2000 through May 2020 was searched using PubMed. Retrospective and observational studies were identified documenting the frequency and treatment of rectal chlamydial infection in MSM, heterosexual men and women that reported lower efficacy of single-dose azithromycin compared to doxycycline. Literature on possible reasons for the lower efficacy were also reviewed including studies of antibiotic resistance, impact of organism load, and persistent infection in rectal specimens and pharmacokinetics and pharmacodynamics of azithromycin in rectal tissue. The available data suggests that single-dose azithromycin is not as effective as azithromycin for the treatment of rectal infection in MSM and women. Most of these data have been retrospective or from observational studies. Final recommendations will depend on the outcome of prospective, randomized, treatment studies. We may also need to examine other dosage regimens for azithromycin.
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (2) , AB163
Chlamydia pneumoniae decreases CD4+ and CD8+ T effector memory IL-2 responses in stimulated peripheral blood mononuclear cells in non-asthmatic subjects
- 1 February 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (2) , AB163
Open AccessChlamydia pneumoniae decreases CD4+ and CD8+ T effector memory IL-2 responses in stimulated peripheral blood mononuclear cells in non-asthmatic subjects
- 1 August 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (8)
In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae
- 1 August 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (8)
In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae
- Open Access
- 1 August 2018
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 37 (8) , 835
Perinatally Acquired Chlamydia trachomatis Infection in Children
- 1 August 2018
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 37 (8) , 835
Open AccessPerinatally Acquired Chlamydia trachomatis Infection in Children
- 1 May 2018
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 70 (3) , 207-211
Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs
Article: Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs - Minerva Pediatrica 2018 June;70(3):207-11 - Minerva Medica - Journals
- 1 May 2018
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 70 (3) , 207-211
Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs
Article: Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs - Minerva Pediatrica 2018 June;70(3):207-11 - Minerva Medica - Journals
- 1 December 2017
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 64 (6) , 1369-1387
New Antimicrobial Agents for the Treatment of Staphylococcal Infections in Children
- 1 December 2017
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 64 (6) , 1369-1387
New Antimicrobial Agents for the Treatment of Staphylococcal Infections in Children